EFFICACY AT THREE YEARS OF DAILY CLINICAL USE OF IGURATIMOD IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Suto, T. [1 ]
Yonemoto, Y. [1 ]
Okamura, K. [1 ]
Tachibana, M. [1 ]
Okura, C. [1 ]
Matsushita, M. [2 ]
Takeuchi, K. [2 ]
Otsuka, K. [2 ]
Ayabe, K. [3 ]
Kaneko, T. [4 ]
Tamura, Y. [4 ]
Inoue, M. [5 ]
Inoue, H. [4 ]
Chikuda, H. [1 ]
机构：
[1] Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, Maebashi, Gunma, Japan
[2] Isesaki Fukushima Hosp, Dept Orthopaed Surg, Isesaki, Japan
[3] Keiyu Hosp, Dept Orthopaed Surg, Tatebayashi, Japan
[4] Inoue Hosp, Dept Orthopaed Surg, Takasaki, Gunma, Japan
[5] Inoue Hosp, Dept Med, Takasaki, Gunma, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6040
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0439
引用
收藏
页码：1203 / 1204
页数：2
相关论文
共 50 条
  • [41] Are prognostic factors in rheumatoid arthritis of any use in daily clinical practice?
    van Riel, P
    NETHERLANDS JOURNAL OF MEDICINE, 2002, 60 (10): : 381 - 382
  • [42] Monitoring the functional capacity of patients with rheumatoid arthritis for three years
    de Oliveira, Leda M.
    Natour, Jamil
    Roizenblatt, Suely
    de Araujo, Pola M. Poll
    Ferraz, Marcos B.
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2015, 55 (01) : 62 - 67
  • [43] Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
    Shrestha, Sajan
    Zhao, Jing
    Yang, Changqing
    Zhang, Jinping
    CLINICAL RHEUMATOLOGY, 2020, 39 (07) : 2139 - 2150
  • [44] Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial
    Xin-Wang Duan
    Xiu-Ling Zhang
    Shao-Yuan Mao
    Jing-Jing Shang
    Xiao-Dong Shi
    Clinical Rheumatology, 2015, 34 : 1513 - 1519
  • [45] Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
    Sajan Shrestha
    Jing Zhao
    Changqing Yang
    Jinping Zhang
    Clinical Rheumatology, 2020, 39 : 2139 - 2150
  • [46] Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise Comment
    Tanaka, Masao
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2021, 10
  • [47] Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis
    Nozaki, Yuji
    Inoue, Asuka
    Kinoshita, Koji
    Funauchi, Masanori
    Matsumura, Itaru
    MODERN RHEUMATOLOGY, 2020, 30 (02) : 249 - 258
  • [48] The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission
    Yoshikawa, Ayaka
    Kotani, Takuya
    Matsuda, Shogo
    Hata, Kenichiro
    Matsumura, Yoko
    Takeuchi, Tohru
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 68 - 73
  • [49] Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice
    Barbich, Tatiana
    Cerda, Osvaldo Luis
    Schneeberger, Emilce Edith
    Citera, Gustavo
    REUMATOLOGIA CLINICA, 2020, 18 (03): : 164 - 168
  • [50] EFFICACY AND SAFETY OF IGURATIMOD AS FIRST-LINE DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR PATIENTS WITH RHEUMATOID ARTHRITIS
    Kobayashi, D.
    Hasegawa, E.
    Wada, Y.
    Ito, S.
    Abe, A.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1008 - 1008
12345